RxDoctor Payments Data

Barry Schulman

Podiatrist · Cleveland, TNNPI 1720081078

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.7% of the total across 150 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 19 manufacturers reported payments, led by Smith+Nephew at 56.5% of the total. Reporting peaked in 2022 at $922 and has fallen 64.8% since, to $325 in 2025.

$3,350in general payments, 2019–2025

Across 150 payments — averaging $22.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Smith+Nephew$2K
  • Organogenesis Inc.$602
  • Amgen$169
  • GRT US Holding, Inc.$90
  • Kerecis Limited$86
  • Paratek Pharmaceuticals, Inc.$82
  • plus $427 from 13 others

What the payments were for

  • Food & beverage$3,341100%
  • Entertainment$90%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,350 in reported general payments places this provider in the 70th percentile of 105 podiatrist providers in Tennessee.

See all podiatrist providers in Tennessee

Medicare billing

Part B allowed, 2024
$202,987
Medicare patients
602
Services billed
3,126

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Linezolid13$1,011
Gentamicin Sulfate22$994
Mupirocin99$807
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip31$696
Cefadroxil63$677
Colchicine22$599
Gabapentin84$542
Ciprofloxacin Hcl42$406
Doxycycline Hyclate40$371
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav32$316
Clindamycin Hcl29$311
Methylprednisolone37$302
Terbinafine Hcl25$298
Pregabalin17$266
Levofloxacin27$147

Paid to pharmacies, not to this prescriber.

Other podiatrist in Cleveland

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →